A phase I pharmacologic study of oral sapacitabine in patients with advanced leukemias or myelodysplastic syndromes.

Trial Profile

A phase I pharmacologic study of oral sapacitabine in patients with advanced leukemias or myelodysplastic syndromes.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2009

At a glance

  • Drugs Sapacitabine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Nov 2009 Results were published in the Journal of Clinical Oncology, according to a Cyclacel Pharmaceuticals media release.
    • 27 Oct 2009 Actual end date (1 Jun 2009) added as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top